{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 7 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 12.3.7.5', 'Evaluations of nAB will be conducted on', 'To reflect that titre', 'those serum samples that test positive for', 'information will not be', 'Anti-drug antibodies', 'ADA. The test sample is deemed positive', 'available from the nAB assay.', 'or negative for the presence of nAb to', 'tralokinumab relative to a pre-determined', '(in assay validation), statistically derived', 'cut point. Samples positive for nAb to', 'tralokinumab are then titrated to determine', 'relative amounts of nAb present in each test', 'sample.', 'Appendix 1', 'Updated with the changes described above,', 'To reflect updated text in the', 'as applicable.', 'protocol.', 'Protocol summary', 'Section 9.9.3 Drug accountability', 'Appendix 7', 'To clarify that used syringes', 'will be destroyed at the trial', 'Country-specific', 'Used syringes will be destroyed at the', 'site in Japan.', 'requirements', 'trial site provided the trial site has', 'procedures in place for such IMP', 'destruction.', 'Trial sites which do not have such IMP', 'destruction procedures in place will', 'dispose used syringes in sharps bins', 'which will be shipped to the contract', 'manufacturing organisation (CMO).', 'In Japan, used syringes will be destroyed', 'at the trial sites.', 'Throughout', 'Minor editorial and document formatting', 'Minor, have therefore not', 'revisions.', 'been summarised.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 8 of 169', 'Table of contents', '1 Clinical trial protocol statement', '2', '1.1 Approval statement LEO Pharma A/S', '2', '1.2 Approval statement international coordinating investigator', '2', '1.3 Acknowledgement statement investigator(s)', '2', 'Protocol amendment summary of changes table', '3', 'Table of contents', '8', 'List of panels', '13', 'List of abbreviations', '14', '2 Trial identification', '17', '3 Schematic of trial design', '17', '4 Schedule of procedures (SoP)', '18', '5 Introduction and rationale', '30', '5.1 Atopic dermatitis', '30', '5.2 Experience with investigational medicinal product', '30', '5.3', 'Trial rationale', '31', '5.4', 'Justification for dose', '32', '5.5 Benefit/risk assessment', '33', '5.6 Ethical considerations', '34', '6 Trial objectives and endpoints', '36', '6.1 Initial treatment period of Weeks 0 to 16', '37', '6.2 Maintenance treatment period of Weeks 16 to 52 for responders at Week 16', '39', '7 Trial design', '40', '7.1 Overall trial design', '40', '7.2 Number of subjects needed', '43', '7.3 End of trial definition', '43', '8 Trial population and withdrawal', '44', '8.1', 'Subject eligibility', '44', '8.2', 'Inclusion criteria', '44', '8.3', 'Exclusion criteria', '46', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 9 of 169', '8.4 Screening, screening failures, and randomisation', '49', '8.5 Discontinuation', '50', '9 Treatments', '52', '9.1 Trial product description', '52', '9.2 Administration of investigational medical products', '53', '9.3', 'Treatment assignment', '55', '9.3.1', 'Blinding', '56', '9.3.2', 'Emergency unblinding of individual subject treatment', '56', '9.4', 'Background treatment (emollients)', '57', '9.5 Concomitant medication and procedures', '57', '9.6 Prohibited medication and procedures', '58', '9.7 Rescue treatment', '59', '9.8 Dose modification and IMP discontinuation rules', '60', '9.8.1 Reasons for permanent discontinuation of IMP', '60', '9.8.2', 'Reasons for temporary discontinuation of IMP', '61', '9.9 Treatment logistics and accountability', '61', '9.9.1', 'Labelling and packaging of IMPs', '61', '9.9.2', 'Storage of IMPs', '61', '9.9.3', 'Drug accountability', '62', '9.9.4', 'Trial product destruction', '63', '9.9.5', 'Treatment compliance', '63', '9.10 Provision for subject care following trial completion', '64', '9.11 Reporting product complaints', '64', '10 Trial schedule and assessments', '65', '10.1 Overview', '65', '10.2 Assessments performed only at screening/baseline', '66', '10.2.1 Columbia-Suicide Severity Rating Scale', '66', '10.2.2 Demographics', '66', '10.2.3 Medical history', '67', '10.2.4 Height and weight', '67', '10.2.5 Body surface area involvement', '67', '10.3 Efficacy assessments', '68', '10.3.1 Investigator assessments', '68', \"10.3.1.1 Investigator's Global Assessment\", '68', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}